Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells

D Chauhan1, H Uchiyama, M Urashima

  • 1Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Insights

Multiple myeloma (MM) cell adhesion to bone marrow stromal cells (BMSCs) triggers interleukin-6 (IL-6) secretion, promoting tumor growth. CD40 signaling, not previously identified adhesion molecules, appears to drive this IL-6 production and MM cell proliferation.

Area of Science:

  • Hematology
  • Cancer Biology
  • Immunology

Background:

  • Multiple myeloma (MM) cells express interleukin-6 (IL-6) receptors and can proliferate in response to IL-6.
  • MM cells adhere to bone marrow stromal cells (BMSCs) via cell surface molecules, which stimulates IL-6 secretion and tumor growth.

Purpose of the Study:

  • To investigate the mechanisms by which MM cell adhesion to BMSCs induces IL-6 secretion.
  • To identify the specific ligand-receptor interactions involved in MM cell-BMSC communication and subsequent IL-6 production.

Main Methods:

  • Flow cytometry to analyze cell surface molecule expression (CD29/CDw49d, CD18/CD11a, CD44, CD40).
  • In vitro co-culture assays of MM cells and BMSCs.
  • Antibody-mediated blockade of cell adhesion molecules.
  • Reporter gene assays (chloramphenicol acetyltransferase) to assess IL-6 gene transcription.
  • Western blotting to analyze NF-kappa B activation.

Main Results:

  • MM cell adhesion to BMSCs significantly increases IL-6 secretion from BMSCs.
  • Antibodies targeting CD29/CDw49d, CD18/CD11a, and CD44 showed minimal effect on BMSC-induced IL-6 secretion.
  • Both MM cells and BMSCs express CD40, and CD40 triggering upregulates IL-6 secretion in both cell types.
  • MM cell adhesion induces IL-6 gene transcription in BMSCs, mediated through the NF-kappa B binding motif.

Conclusions:

  • CD40 signaling is a critical pathway for IL-6 secretion induced by MM cell-BMSC interaction.
  • This CD40-mediated IL-6 production may contribute to both autocrine and paracrine MM cell growth.
  • Targeting the CD40 pathway could represent a novel therapeutic strategy for multiple myeloma.